Breaking News
Quotes
All Instrument Types
  • All Instrument Types
  • Indices
  • Equities
  • ETFs
  • Funds
  • Commodities
  • Currencies
  • Crypto
  • Bonds
  • Certificates

Please try another search

Search website for: 
Popular News
More
Popular Analysis
More
More
Get 40% Off
/Free Sign Up
 0
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list
Close

Crispr Therapeutics AG (1CG)

Create Alert
Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Create Manage my alerts 
Back
Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
 
Create New Watchlist Create
Create a new holdings portfolio Add Create
+ Add another position Close
Crispr Therapeutics historical data, for real-time data please try another search
40.0000 0.0000    0.00%
28/06 - Delayed Data. Currency in EUR ( Disclaimer )
Type:  Equity
Market:  Germany
ISIN:  CH0334081137 
S/N:  A2AT0Z
  • Volume: 0
  • Bid/Ask: 41.0000 / 41.2000
  • Day's Range: 39.4000 - 40.0000
Crispr Therapeutics 40.0000 0.0000 0.00%

NASDAQ:1CG Financials

 
A brief overview of the NASDAQ:CRSP financials. This summary provides an overview of the most significant critical numbers from each of its financial reports, including the income statement, balance sheet, and cash flow statement. Additionally, it features several financial ratios that provide insight into the company's financial health. Users can select to view data from four periods of either annual or quarterly information, allowing them to track financial performance of Crispr Therapeutics AG over time.

CRISPR Therapeutics AG reported earnings results for the full year ended December 31, 2023. For the full year, the company reported revenue was USD 371.21 million compared to USD 1.2 million a year ago. Net loss was USD 153.61 million compared to USD 650.18 million a year ago. Basic loss per share from continuing operations was USD 1.94 compared to USD 8.36 a year ago. Diluted loss per share from continuing operations was USD 1.94 compared to USD 8.36 a year ago.

AnnualQuarterly  
InvestingPro Advanced Financial Summary
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

1CG Income Statement

Gross margin TTM -39.43%
Operating margin TTM -
Net Profit margin TTM -
Return on Investment TTM -
 Total Revenue  Net Income
Period Ending: Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023
Total Revenue 201.21 70 100
Gross Profit 86.06 -114.12 -76.19 -42.13
Operating Income 69.58 -132.41 -95.22 -64.49
Net Income 89.35 -112.15 -77.74 -53.06

1CG Balance Sheet

Quick Ratio MRQ -
Current Ratio MRQ 17.54
LT Debt to Equity MRQ -
Total Debt to Equity MRQ -
 Total Assets  Total Liabilities
Period Ending: Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023
Total Assets 2229.57 2086.83 2197.01 2244.36
Total Liabilities 346.77 359.04 380.99 389.47
Total Equity 1882.8 1727.79 1816.03 1854.9

1CG Cash Flow Statement

Cash Flow/Share TTM -
Revenue/Share TTM -
Operating Cash Flow  -88.31%
 Cash  Net Change in Cash
Period Ending: Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023
Period Length: 0 Months 0 Months 0 Months 0 Months
Cash From Operating Activities -96.07 -39.86 -133.24 8.8
Cash From Investing Activities -81.45 121.35 216.92 117.83
Cash From Financing Activities 38.94 1.56 16.76 5.4
Net Change in Cash -138.53 83 100.47 132.06
* In Millions of USD (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

I Agree

CRSP Comments

Write your thoughts about CRISPR Therapeutics AG
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Anthony Hernandez
Anthony Hernandez Jan 05, 2024 10:06AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Editing your genes to live a longer? Or all the gold in the world?
Reply
2 2
Report
John Brand
John Brand Dec 14, 2023 6:48AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Gap filled.
Reply
1 1
Report
fth Jung
fth Jung Dec 11, 2023 11:38AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Absurd
Reply
2 0
Report
Mark Mallonee
Mark Mallonee Dec 08, 2023 4:30PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Take note that another sickle cell stock, a compeititor to CRISPR, was ALSO approved today. It ALSO plummeted today in value, by 40%!The reasons for these drops are vastly different in the end and are why CRISPR is showing to be the likely winner in this field for 2 reasons:- Bluebird earned a black box warning for certain kinds of blood cancer today with its approval. I am a second year pharmacy student. In case you don’t know what a black box warning is, it’s the most dangerous, important, in your face side effect that practitioners MUST see before they prescribe treatments. This BBW is particularly nasty it seems, truly.- It has been announed that CRISPR will be almost 1 million dollars cheaper than bluebird’s treatment. That is huge. Bluebird will cost 3.1 million for treatment and CRISPR will cost 2.2 million for treatment. Bluebird costs more and has a horrib black box warning. CRISPR is cheaper and had NO black box warning given to it today. CRISPR is the obvious choice.
Reply
8 1
Report
Mark Mallonee
Mark Mallonee Dec 08, 2023 4:30PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
That other company is bluebird, in case I did not make it clear at the start of my comment.
Reply
0 0
Report
Simon Frandsen
Simon Frandsen Dec 08, 2023 4:30PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Thanks for good info and thoughts Mark
Reply
0 0
Report
Robby Lester
Robby Lester Dec 08, 2023 2:39PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Took profits. Buy back in at $50
Reply
0 0
Report
Otis Grant
Otis Grant Dec 08, 2023 1:06PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Dont panic the same thing happened with the UK approval. The rally took a little bit to start
Reply
0 0
Report
fth Jung
fth Jung Dec 08, 2023 1:06PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
How long?
Reply
0 0
Report
Mark Mallonee
Mark Mallonee Dec 08, 2023 11:54AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Anyone able to determine why the drop?
Reply
0 0
Report
Grape Ape
Grape Ape Dec 08, 2023 11:54AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Options tomfoolery. The zero day derivatives market has gotten cartoonishly large.
Reply
1 0
Report
Nicholas Murphy
Nicholas Murphy Dec 08, 2023 11:54AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
They slashed 10% of their staff. Never good. But FDA approval is huge. Just have faith in the play. Takes a while for the big boys to get in.
Reply
1 0
Report
Luca Origo
Luca Origo Dec 08, 2023 11:49AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
It should skyrocket 30% up and it goes down wtf
Reply
0 0
Report
Grape Ape
Grape Ape Dec 08, 2023 11:47AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Brutal, lol
Reply
0 0
Report
Grape Ape
Grape Ape Dec 08, 2023 11:40AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Gotta love approving a Nobel award winning, first of its kind DNa editing treatment for nearly 100,000 people means an instant 8% drop, lol. Guess we just gotta hold and wait.
Reply
2 0
Report
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Cancel Attach
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Confirm Block Cancel
Ok
Report this comment

I feel that this comment is:

Submit
Comment flagged

Thank You!

Your report has been sent to our moderators for review
Close
Continue with Google
or
Sign up with Email